MEDIAN Technologies has been selected to provide imaging services in a Phase III trial sponsored by a U.S.-based specialty pharmaceutical company, in a transaction valued at $870,400.   Imaging data will be acquired from approximately 24 clinical sites in Europe and Asia, which is expected to enroll 200 patients. MEDIAN will provide clinical site qualification and training, image data collection, quality control, centralized data storage, and Independent Central Review (ICR) services using its L...